Message

Isaac Merritt

29th Sep, 19

$PFE Reveals findings from pivotal study testing abrocitinib in patients with moderate to severe atopic dermatitis- http://crweworld.com/article/news-provided-by-business-wire/1254377/pfizer-announces-positive-top-line-results-from-second-pivotal-phase-3-study-of-investigational-oral-jak1-candidate-abrocitinib-in-patients-aged-12-and-older-with-moderate-to-severe-atopicn-dermatitis